Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIIB115 intrathecal safety, tolerability, and pharmacokinetics study
NL-OMON60628Phase 1Active, not recruiting
- Sponsor
- Biogen
- Start
- Jun 2024
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of salanersen in spinal muscular atrophy (SMA) (3 arms), sponsored by Biogen. Primary endpoint: Number of participants with adverse events and serious adverse events. Started Jun 2024; status: active, not recruiting.
02
Drugs
salanersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NL-OMON60628.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60628.